Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.

Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives

Open access
Drygalski, Krzysztof · 2025 · International Journal of Molecular Sciences

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment is currently approved. This narrative review provides an overview of emerging pharmacological treatments under clinical investigation, with a particular focus on agents recently evaluated in randomized clinical trials. A systematic search of the ClinicalTrials.gov database through to April 2025 was conducted to identify relevant studies. Investigational drugs were categorized by their molecular mechanisms, and data on efficacy, safety, and clinical development phases were summarized. The most extensively studied drug classes include GLP-1 receptor agonists, PPAR agonists, and FXR agonists, as well as inhibitors of ACC and DGAT. These therapies have shown promising effects on hepatic steatosis, liver enzyme levels, and metabolic markers and may be introduced into clinical practice in the near future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms26136518

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Progression of MAFLD according to the “multiple-hit” theory.
Figure 1 Progression of MAFLD according to the “multiple-hit” theory.CC BY · PubMed Central
Figure 2 Non-invasive evaluation of liver fibrosis risk.
Figure 2 Non-invasive evaluation of liver fibrosis risk.CC BY · PubMed Central
Figure 3 Main molecular effects of new, experimental drugs in MASLD.
Figure 3 Main molecular effects of new, experimental drugs in MASLD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 141 references

Cited by

See all 49

Metadata

Authors
Drygalski, K.
Affiliations
Gdańsk Medical University (PL)
Corresponding author
Drygalski, Krzysztof
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2025-07-07
Volume
26
Issue
13
Pages
6518
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4412088572
Cited by
39
References
141
Citations by year
2026: 34 · 2025: 5
FWCI
5.95
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Servier
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
non-alcoholic fatty liver disease, pharmacotherapy, GLP-1 receptor agonists, PPAR agonists, FXR agonists, acetyl-CoA carboxylase inhibitors, hepatic steatosis, drug development, obesity, type 2 diabetes, metabolic syndrome
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Humans, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. https://app.cochat.ai/papers/10.3390/ijms26136518
The paper
Drygalski, K. (2025). Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136518

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.